Proper Name: Dengue Tetravalent Vaccine, Live
Indication: To include data on the immune response to Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel) when administered concomitantly with DENGVAXIA.
DENGVAXIA is used for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4. DENGVAXIA is approved for use in individuals 6 through 16 years of age with laboratory-confirmed previous dengue infection and living in endemic areas.
Approval Date: 01/25/2023
Manufacturer: Sanofi Pasteur Inc.